PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $137 | -11.6% | 13,235 | +22.4% | 0.00% | – |
| Q2 2023 | $155 | +74.2% | 10,813 | -13.7% | 0.00% | – |
| Q1 2023 | $89 | -11.0% | 12,526 | +41.1% | 0.00% | – |
| Q4 2022 | $100 | -99.1% | 8,879 | +809.7% | 0.00% | – |
| Q3 2022 | $11,000 | -72.5% | 976 | -79.5% | 0.00% | – |
| Q2 2022 | $40,000 | -57.4% | 4,767 | -31.6% | 0.00% | – |
| Q1 2022 | $94,000 | – | 6,967 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 4,901,358 | $41,368,000 | 8.59% |
| Frazier Life Sciences Management, L.P. | 5,827,415 | $49,183,000 | 4.64% |
| Abingworth LLP | 1,435,106 | $12,112,000 | 3.88% |
| Penn Mutual Asset Management | 86,940 | $734,000 | 0.99% |
| 683 Capital Management, LLC | 1,440,000 | $12,153,000 | 0.86% |
| Western Standard LLC | 109,055 | $920,000 | 0.70% |
| MPM BioImpact LLC | 193,326 | $1,632,000 | 0.45% |
| Newtyn Management, LLC | 255,767 | $2,159,000 | 0.41% |
| StepStone Group LP | 422,085 | $3,562,000 | 0.38% |
| Avidity Partners Management LP | 1,919,800 | $16,203,000 | 0.37% |